Results 151 to 160 of about 10,444 (219)
Mometasone furoate nasal spray for the treatment of asthma
Expert Opinion on Investigational Drugs, 2016 Asthma is a common respiratory disease characterized by airway inflammation, bronchoconstriction and airway hyperresponsiveness and symptoms such as coughing, wheezing, shortness of breath and chest tightness. Allergic rhinitis is a common comorbidity in asthma and glucocorticoids are the key stone in the treatment of both diseases.
Howraman Meteran, Vibeke Backer
exaly +5 more sources
Scandinavian Journal of Gastroenterology, 2021 Objectives Topical corticosteroids are considered a cornerstone in the treatment of patients with eosinophilic esophagitis. The aim of this study was to evaluate the benefit of using mometasone furoate spray versus placebo on dysphagia and health-related
Jakob Tytor +4 more
semanticscholar +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pulmonary Pharmacology & Therapeutics, 2022
To investigate the pharmacokinetics and effects on the hypothalamic-pituitary-adrenal (HPA) axis of mometasone furoate (MF), fluticasone propionate (FP) and fluticasone furoate (FF).Study 1: Fourteen healthy participants received inhaled and intravenous MF (inhaled dose via Twisthaler) and FP (inhaled dose via Diskus), both given at 400 μg, using a ...
Peter T, Daley-Yates +3 more
openaire +3 more sources
To investigate the pharmacokinetics and effects on the hypothalamic-pituitary-adrenal (HPA) axis of mometasone furoate (MF), fluticasone propionate (FP) and fluticasone furoate (FF).Study 1: Fourteen healthy participants received inhaled and intravenous MF (inhaled dose via Twisthaler) and FP (inhaled dose via Diskus), both given at 400 μg, using a ...
Peter T, Daley-Yates +3 more
openaire +3 more sources
Drugs, 2008
Mometasone furoate (Nasonex) is a high-potency intranasal corticosteroid available for the treatment and/or prophylaxis of the nasal symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). In the EU, it is approved for use in patients aged > or =6 years and, in the US, it is approved as a treatment in patients aged > or =2 ...
Claudine M, Baldwin, Lesley J, Scott
openaire +3 more sources
Mometasone furoate (Nasonex) is a high-potency intranasal corticosteroid available for the treatment and/or prophylaxis of the nasal symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). In the EU, it is approved for use in patients aged > or =6 years and, in the US, it is approved as a treatment in patients aged > or =2 ...
Claudine M, Baldwin, Lesley J, Scott
openaire +3 more sources
Expert Review of Clinical Immunology, 2023
Introduction Allergic rhinitis (AR) is a common disease with an important impact on the quality of life and very high management costs. In many patients, the poor control of rhinitis symptoms often requires the use of different drugs, and polytherapy ...
E. Ridolo +6 more
semanticscholar +1 more source
Introduction Allergic rhinitis (AR) is a common disease with an important impact on the quality of life and very high management costs. In many patients, the poor control of rhinitis symptoms often requires the use of different drugs, and polytherapy ...
E. Ridolo +6 more
semanticscholar +1 more source